Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review

Diabetes Research and Clinical Practice

Volumn 121, Issue , 2016, Pages 27-34

  Bihan, Helene ^a,b,c   Ng, Winda L ^a,d   Magliano, Dianna J ^a,d   Shaw, Jonathan E ^a,d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b AVICENNE HOSPITAL   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Determinant factors; Diabetes; Efficacy; Incretin therapy

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 1A; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INCRETIN;

AGE; ASIAN; BODY MASS; CAUCASIAN; CHINESE; DRUG EFFICACY; ETHNIC DIFFERENCE; ETHNICITY; FRANCE; HEMOGLOBIN DETERMINATION; HUMAN; INDIAN; MEDICAL HISTORY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHILIPPINES; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; AGONISTS; BLOOD; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; TREATMENT OUTCOME;

EID: 84986593868     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.08.011     Document Type: Review

References (44)

1. [1] Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32 (2009), 193–203.
2. [2] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycemia in Type 2 diabetes: a patient-centered approach. Diabetes Care 35 (2012), 1364–1379.
3. [3] Kim, Y.G., Hahn, S., Oh, T.J., Kwak, S.H., Park, K.S., Cho, Y.M., Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56 (2013), 696–708.
4. [4] Esposito, K., Chiodini, P., Capuano, A., Maiorino, M.I., Bellastella, G., Giugliano, D., Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: meta-regression analysis of 78 randomized controlled trials with 20,053 patients. Endocrine 46 (2014), 43–51.
5. [5] Monami, M., Dicembrini, I., Martelli, D., Mannucci, E., Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 27:Suppl. 3 (2011), 57–64.
6. [6] National Collaborating Centre for Methods and Tools, Quality assessment tool for quantitative studies method. 2008, McMaster University, Hamilton, ON Retrieved from < http://www.nccmt.ca/registry/view/eng/15.html.2010>.
7. [7] Barzilai, N., Guo, H., Mahoney, E.M., Caporossi, S., Golm, G.T., Langdon, R.B., et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 27 (2011), 1049–1058.
8. [8] Jeon, H.J., Oh, T.K., Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J 35 (2011), 529–535.
9. [9] Garber, A.J., Foley, J.E., Banerji, M.A., Ebeling, P., Gudbjörnsdottir, S., Camisasca, R.-P., et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 10 (2008), 1047–1056.
10. [10] Pratley, R.E., Kipnes, M.S., Fleck, P.R., Wilson, C., Mekki, Q., Alogliptin Study 007 Group, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 11 (2009), 167–176.
11. [11] Fonseca, V., Schweizer, A., Albrecht, D., Baron, M.A., Chang, I., Dejager, S., Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50 (2007), 1148–1155.
12. [12] Pan, C., Xing, X., Han, P., Zheng, S., Ma, J., Liu, J., et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 14 (2012), 737–744.
13. [13] Liu, S.-C., Chien, K.-L., Wang, C.-H., Chen, W.-C., Leung, C.-H., Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 19 (2013), 980–988.
14. [14] Bajaj, M., Gilman, R., Patel, S., Kempthorne-Rawson, J., Lewis-D'Agostino, D., Woerle, H.-J., Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med J Br Diabet Assoc 31 (2014), 1505–1514.
15. [15] Kozlovski, P., Foley, J., Shao, Q., Lukashevich, V., Kothny, W., Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes 4 (2013), 151–156.
16. [16] Yki-Järvinen, H., Rosenstock, J., Durán-Garcia, S., Pinnetti, S., Bhattacharya, S., Thiemann, S., et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ⩾52-week randomized, double-blind study. Diabetes Care 36 (2013), 3875–3881.
17. [17] Bolli, G., Dotta, F., Colin, L., Minic, B., Goodman, M., Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 11 (2009), 589–595.
18. [18] Odawara, M., Hamada, I., Suzuki, M., Efficacy and safety of vildagliptin as add-on to metformin in Japanese patients with type 2 diabetes mellitus. Diabetes Ther Res Treat Educ Diabetes Relat Disord 5 (2014), 169–181.
19. [19] Pan, C., Yang, W., Barona, J.P., Wang, Y., Niggli, M., Mohideen, P., et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med J Br Diabet Assoc 25 (2008), 435–441.
20. [20] Pan, C.Y., Yang, W., Tou, C., Gause-Nilsson, I., Zhao, J., Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 28 (2012), 268–275.
21. [21] Pratley, R.E., Reusch, J.E.-B., Fleck, P.R., Wilson, C.A., Mekki, Q., Alogliptin Study 009 Group, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 25 (2009), 2361–2371.
22. [22] Rosenstock, J., Baron, M.A., Dejager, S., Mills, D., Schweizer, A., Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30 (2007), 217–223.
23. [23] Aschner, P., Kipnes, M.S., Lunceford, J.K., Sanchez, M., Mickel, C., Williams-Herman, D.E., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29 (2006), 2632–2637.
24. [24] Del Prato, S., Barnett, A.H., Huisman, H., Neubacher, D., Woerle, H.-J., Dugi, K.A., Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 13 (2011), 258–267.
25. [25] Dobs, A.S., Goldstein, B.J., Aschner, P., Horton, E.S., Umpierrez, G.E., Duran, L., et al. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. J Diabetes 5 (2013), 68–79.
26. [26] Iwamoto, Y., Kashiwagi, A., Yamada, N., Terao, S., Mimori, N., Suzuki, M., et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes Metab 12 (2010), 700–708.
27. [27] Mohan, V., Yang, W., Son, H.-Y., Xu, L., Noble, L., Langdon, R.B., et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 83 (2009), 106–116.
28. [28] Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 (2006), 2564–2571.
29. [29] Seino, Y., Fujita, T., Hiroi, S., Hirayama, M., Kaku, K., Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 27:Suppl. 3 (2011), 21–29.
30. [30] Kaku, K., Itayasu, T., Hiroi, S., Hirayama, M., Seino, Y., Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab 13 (2011), 1028–1035.
31. [31] Bergenstal, R., Lewin, A., Bailey, T., Chang, D., Gylvin, T., Roberts, V., et al. Efficacy and safety of biphasic insulin Aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 25 (2009), 65–75.
32. [32] Bergenstal, R.M., Wysham, C., Macconell, L., Malloy, J., Walsh, B., Yan, P., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376 (2010), 431–439.
33. [33] Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 96 (2011), 1301–1310.
34. [34] Buse, J.B., Drucker, D.J., Taylor, K.L., Kim, T., Walsh, B., Hu, H., et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33 (2010), 1255–1261.
35. [35] Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S., Baron, A.D., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004), 2628–2635.
36. [36] Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005), 1083–1091.
37. [37] Rosenstock, J., Shenouda, S.K., Bergenstal, R.M., Buse, J.B., Glass, L.C., Heilmann, C.R., et al. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 35 (2012), 955–958.
38. [38] Drucker, D.J., Buse, J.B., Taylor, K., Kendall, D.M., Trautmann, M., Zhuang, D., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372 (2008), 1240–1250.
39. [39] Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375 (2010), 2234–2243.
40. [40] Thompson, S.G., Higgins, J.P.T., How should meta-regression analyses be undertaken and interpreted?. Stat Med 21 (2002), 1559–1573.
41. [41] Lim, S., An, J.H., Shin, H., Khang, A.R., Lee, Y., Ahn, H.Y., et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf) 77 (2012), 215–223.
42. [42] Maeda, H., Kubota, A., Tanaka, Y., Terauchi, Y., Matsuba, I., ASSET-K Study Group, The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 95 (2012), e20–2.
43. [43] Gautier, J.-F., Sauvanet, J.-P., Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes. Ann Endocrinol 72 (2011), 287–295.
44. [44] Shaw, J.E., Bloomgarden, Z.T., Individualizing therapy: do we have the tools to do it?. J Diabetes 7 (2015), 1–2.